2024年12月16日 · Molnupiravir has been issued and Emergency Use Authorization to be used to treat mild to moderate COVID-19 in patients at risk of developing severe COVID-19 illness. Lagevrio should be started within 5 days of symptoms starting.

2022年1月5日 · Molnupiravir is authorized for the treatment of mild-to-moderate COVID-19 in adults 18 and older who are at high risk for progressing to severe COVID-19, including hospitalization or death. It is not authorized for children and teenagers younger than 18 years because it may affect bone and cartilage growth.

2023年8月23日 · Molnupiravir is an experimental medicine being studied for the treatment of mild-to-moderate COVID-19. Includes molnupiravir side effects, interactions, and indications.

Molnupiravir, sold under the brand name Lagevrio, is an antiviral medication that inhibits the replication of certain RNA viruses. [7] It is used to treat COVID‑19 in those infected by SARS-CoV-2. [7] It is taken by mouth. [7]

Early treatment with molnupiravir (800 mg, twice daily for 5 days) could decrease the risk of hospitalization or mortality in mild-to-moderate COVID-19 patients with one or more risk factors for progression to severe forms of the disease.

2024年9月9日 · We aimed to report the effect of molnupiravir treatment for COVID-19 on wellbeing, severe and persistent symptoms, new infections, health care and social service use, medication use, and time off work at 3 months and 6 months post-randomisation.

2025年2月1日 · Molnupiravir is used to treat mild to moderate coronavirus disease 2019 (COVID-19) in non-hospitalized patients who are at high risk for progression to severe COVID-19 (eg, hospitalization, death) or in patients for whom other authorized or approved COVID-19 vaccines are not accessible or appropriate.

2022年2月10日 · Background: New treatments are needed to reduce the risk of progression of coronavirus disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is active against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2022年3月10日 · On December 23, 2021, molnupiravir was granted the FDA Emergency Use Authorization (EUA) for the treatment of mild to moderate COVID-19 patients, who are at high risk of progressing to severe disease, when other antiviral therapies are not accessible or …

6 天之前 · The oral antiviral prescription drug, Lagevrio or molnupiravir (MOV), and the combination antiviral drug nirmatrelvir/ritonavir or Paxlovid (PAX) have been administered to millions of patients with mild-to-moderate COVID-19 during and after the pandemic and both are in continuous use to date.